Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage...

All performance and safety endpoints were met in A.D.O.P.T. Pivotal Trial Study Phase; other key findings include 95% first-stick success and 98% patient acceptance.

For more information, please visit thermofisher.com/extendedbloodtyping and read the white paper, “Genotyping for extended and rare blood types.”

In a world overpopulated by pathogens, the human immune system has evolved to protect against pathogens that are, themselves, continually evolving. Host immune response to infection...

Weight loss medication reduced both day and nighttime blood pressure levels, finds new study in the journal Hypertension.

Researchers used genetic markers in maternal blood that serve as “stand-ins” for brain molecules.

The blood-brain barrier is a filtering mechanism of the capillaries that carry blood to the brain and spinal cord tissue while blocking the passage of certain toxic substances...

HORIBA Medical’s new HELO 2.0 modular high throughput automated hematology platform is CE-IVDR approved.

Quest Mobile has 5,000 trained mobile phlebotomists whose reach will extend to 44 states by the end of 2023.

AABB23 protocols.